Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers.
Stockholm, Sweden - 10 June 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures. This partnership aims to accelerate research and development in the area of innovative treatments for various illnesses. The PDC Center for High Performance Computing (PDC) at KTH hosts the most powerful supercomputer within the National